The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGym Grp Share News (GYM)

Share Price Information for Gym Grp (GYM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 113.00
Bid: 111.40
Ask: 112.80
Change: 0.20 (0.18%)
Spread: 1.40 (1.257%)
Open: 113.00
High: 113.00
Low: 113.00
Prev. Close: 112.80
GYM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Revenue rises, losses narrow for the Gym Group

Wed, 13th Mar 2024 09:35

(Sharecast News) - Low-cost gym operator the Gym Group reported an 18% increase in revenue in its full-year results on Wednesday, reaching £204m.

The London-listed company said group adjusted EBITDA rose 6% to £75.5m, while adjusted EBITDA less normalised rent reached £38.5m, ahead 1% year-on-year.

Its adjusted loss before tax remained consistent with the prior year at £5.5m, while statutory losses before tax improved by 57% to £8.3m.

Similarly, statutory losses after tax increased 56% to £8.4m, while adjusted basic and diluted losses per share rose by 13% to 3.4p.

Free cash flow surged 62% to £27m, with non-property net debt narrowing by 13% to £66.4m.

On the operational front, the Gym Group saw average members increase by 8%, with average revenue per member per month (ARPMM) rising 9%.

Like-for-like revenue grew 8%, and despite cost inflation, particularly in utilities and staff expenses, EBITDA less normalised rent was slightly ahead of 2022.

The company said its business strategy for the future, dubbed 'Next Chapter', aimed for a threefold growth plan focussed on strengthening the core business, accelerating the rollout of quality sites, and broadening growth opportunities by exploring additional revenue streams.

During the year, the company bolstered its leadership team with key appointments, including Will Orr as chief executive officer and Simon Jones as a non-executive director.

Additionally, Alison Sagar was set to join as chief commercial officer in March.

Looking ahead, the Gym Group reported a positive start to trading in 2024, with revenue after two months increasing by 16% year-on-year.

The company said it anticipated a 4% to 5% overall increase in like-for-like revenue for the year.

Plans for 2024 included opening 10 to 12 new sites, with leverage expected to remain within the range of 1.5 to 2.0x.

The 'Next Chapter' growth plan aimed to deliver 50 site openings with an average return on invested capital of 30% over three years, funded from free cash flow.

"We have maintained positive momentum in revenue through the second half to deliver results that have offset cost inflation, in line with our guidance," said chief executive officer Will Orr.

"With a strong start to 2024, and clear signs that demand for health and fitness has never been stronger, these are solid foundations on which to build our 'Next Chapter' growth plan."

Orr said that over the next three years, the firm aimed to strengthen the performance of its core business and accelerate its site rollout.

"There continues to be substantial headroom for low cost gyms in the UK and we are fully focused on our aim of making high value, low cost fitness even more accessible for all."

At 0913 GMT, Gym Group shares were up 5.47% at 115.6p.

Reporting by Josh White for Sharecast.com.

More News
23 Nov 2020 17:01

LONDON MARKET CLOSE: FTSE Trails Peers As Vaccine Boost Wanes

LONDON MARKET CLOSE: FTSE Trails Peers As Vaccine Boost Wanes

Read more
17 Nov 2020 15:50

DIRECTOR DEALINGS: Gym Group Founder Treharne Sells GBP2 Million Worth

DIRECTOR DEALINGS: Gym Group Founder Treharne Sells GBP2 Million Worth

Read more
11 Nov 2020 13:58

Wednesday broker round-up

(Sharecast News) - easyJet: Bank of America Merrill Lynch upgrades to buy.

Read more
11 Nov 2020 09:45

UK BROKER RATINGS SUMMARY: Goldman Sachs And BofA Both Lift IAG To Buy

UK BROKER RATINGS SUMMARY: Goldman Sachs And BofA Both Lift IAG To Buy

Read more
9 Nov 2020 12:27

Gym Group Expresses Confidence As It Temporarily Closes England Gyms

Gym Group Expresses Confidence As It Temporarily Closes England Gyms

Read more
9 Nov 2020 10:05

Gym Group loses 37,000 members in two months

(Sharecast News) - The Gym Group lost 37,000 members in September and October as Covid-19 cases rose and the prospect of further restrictions loomed.

Read more
23 Oct 2020 11:59

LONDON MARKET MIDDAY: Virus Drug News Lifts FTSE As Lenders Lead Way

LONDON MARKET MIDDAY: Virus Drug News Lifts FTSE As Lenders Lead Way

Read more
7 Oct 2020 18:20

UK TRADING UPDATE SUMMARY: Gym Group Fighting Fit With Fresh York Unit

UK TRADING UPDATE SUMMARY: Gym Group Fighting Fit With Fresh York Unit

Read more
10 Sep 2020 20:16

DIRECTOR DEALINGS: Gym Group Founder Sells 275,000 Shares

DIRECTOR DEALINGS: Gym Group Founder Sells 275,000 Shares

Read more
2 Sep 2020 09:20

Gym Group Swings To Loss On Lockdown Weight But Emerges Fighting Fit

Gym Group Swings To Loss On Lockdown Weight But Emerges Fighting Fit

Read more
2 Sep 2020 09:13

The Gym Group swings to interim loss as Covid-19 hits revenues

(Sharecast News) - The Gym Group swung to an interim loss this year after the budge workout centres operator was forced to shutter all of its locations in late March as a result of the Covid-19 pandemic.

Read more
26 Aug 2020 15:57

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
24 Jul 2020 13:59

Friday broker round-up

(Sharecast News) - Unilever: Barclays upgrades to overweight with a target price of 5,470.0p.

Read more
24 Jul 2020 09:38

UK BROKER RATINGS SUMMARY: Barclays Raises Phoenix And Cuts M&G

UK BROKER RATINGS SUMMARY: Barclays Raises Phoenix And Cuts M&G

Read more
10 Jul 2020 17:06

LONDON MARKET CLOSE: Stocks Rise As Gilead's Remdesivir Shows Promise

LONDON MARKET CLOSE: Stocks Rise As Gilead's Remdesivir Shows Promise

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.